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Purpose: To observe the late toxicities in nasopharyngeal carcinoma (NPC) patients who achieved long-term survival
after intensity modulated radiation therapy (IMRT).
Methods: 208 untreated NPC patients who received IMRT and survived more than five years with locoregional disease
control and no metastasis were evaluated in this study. The prescription dose to the gross target volume of nasopharynx
(GTVnx), positive neck lymph nodes (GTVnd), clinical target volume 1 (CTV1) and 2 (CTV2) was 68Gy/30f, 60-66Gy/30f,
60 Gy/30f and 54Gy/30f, respectively. The nasopharynx and upper neck targets were irradiated using IMRT, and the lower
neck and supraclavicular fossae targets were irradiated using the half-beam technique with conventional irradiation. The
late toxicities were evaluated according to the LENT/SOMA criteria of 1995.
Results: The median follow-up time was 78 months (60–96 months). The occurrence rates of cervical subcutaneous
fibrosis, hearing loss, skin dystrophy, xerostomia, trismus, temporal lobe injury, cranial nerve damage, cataract, and brain
stem injury induced by radiotherapy were 89.9%, 67.8%, 47.6%, 40.9%, 7.21%, 4.33%, 2.88%, 1.44%, and 0.48%, respectively.
No spinal cord injury and mandible damage were found. Grade 3–4 late injuries were observed as follows: 1 (0.48%)
skin dystrophy, 4 (1.92%) cervical subcutaneous fibrosis, 2 (0.96%) hearing loss, 2 (0.96%) cranial nerve palsy, and 1 (0.48%)
temporal lobe necrosis. No grade 3–4 late injuries occurred in parotid, temporomandibular joints and eyes. Xerostomia
decreased gradually over time and then showed only slight changes after 4 years. The change in the incisor distance
stabilised by 1 year after RT, however, the incidence of hearing loss, skin dystrophy, subcutaneous fibrosis and nervous
system injuries increased over time after RT.
Conclusion: The late injuries in most NPC patients who had long-term survivals after IMRT are alleviated. Within the
5 years of follow-up, we found xerostomia decreased gradually; The change in the incisor distance stabilised by 1 year
after RT; while hearing loss, nervous system injuries increased over time after RT.
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Nasopharyngeal cancer (NPC) is one of the most im-
portant head and neck cancers in China. More than 50%
of NPC patients treated with two-dimensional radiation
therapy (2-D RT) achieved long-term survival [1]. How-
ever, late adverse events are obvious in these surviving
NPC patients and greatly affect their quality of life [2].
For example, 30%-40% of the surviving NPC patients* Correspondence: zhaochong@sysucc.org.cn
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unless otherwise stated.had late injuries of the neural system [2], and 36% of the
surviving NPC patients had grade 3–4 non-neural
system injuries [3], which resulted in 1-3% potential
lethal damage in these patients [4,5]. Treatments to alle-
viate late injuries after RT and to improve the tumour
control rate are a primary focus of current studies.
Intensity modulated radiation therapy (IMRT), which
was developed to improve the local tumour control rate
and the quality of life, has been widely adapted in NPC
treatment in recent decades. Compared with 2-D RT,
IMRT effectively lowers the exposure dose of normal
tissues around the tumour, such as the parotid glandsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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only clearly alleviates acute RT injuries, such as xerosto-
mia, during the middle and later periods of RT [10] but
also remarkably reduces the degree of late injuries more
than six months after RT [6-12]. However, many reports
regarding the late injuries of NPC patients after IMRT
had short follow-up periods. We observed the long-term




From February 2003 to March 2007, 208 untreated NPC
patients who received IMRT in the Department of Radi-
ation Oncology of Sun Yat-Sen University Cancer Centre
and who survived more than five years with locoregional
disease control and no metastasis were included in this
study. This patient group was composed of 167 male and
41 female patients. The median age was 42 years (range:
13–73 years). According to the Union for International
Cancer Control (UICC) 2002 staging criteria, 14 patients
were stage I, 82 patients were stage II, 86 patients were
stage III, 25 patients were stage IVa, and 1 patient was
stage IVb (Table 1).
The exposure dose of the target region and the organs
at-risk
All of the patients received definitive external irradiation.
The nasopharynx and upper neck targets were irradiated
using the simultaneous modulated accelerated radiation
therapy (SMART) boost IMRT technique, and the lower
neck and supraclavicular fossae targets were irradiated
using the half-beam technique with conventional 2-D
irradiation.
The patient immobilisation, CT simulation and target
volume delineation details have been described previously
by Zhao [10] and Xiao [13]. The brainstem, spinal cord,
optic nerves, optic chiasm, pituitary, temporal lobes, lens,
parotids, TMJs and mandible were contoured as organs at
risk (OARs).
The target volume prescription doses of the gross
tumour volume of the nasopharynx (GTVnx), the gross
tumour volume of the involved lymph nodes (GTVnd),
clinical target volume 1 (CTV1, the area from 0.5 cm to
1.0 cm outside the GTV that involves the potential sites ofTable 1 T/N stage distribution of 208 patients
Stage T1 T2 T3 T4 Total
N0 14 35 18 4 71
N1 10 37 26 15 88
N2 3 25 14 6 48
N3 1 0 0 0 1
Total 28 97 58 25 208local infiltration) and clinical target volume 2 (CTV2, the
margin from 0.5 cm to 1.0 cm around CTV1 and the
lymph node draining area (Levels II, III, and IV)) were
68 Gy, 60–66 Gy, 60 Gy and 54 Gy, respectively. In total,
30 fractions were administered at 1 fraction daily, 5 days/
week. The maximum doses to OARs, which were restricted
to prevent exceeding their tolerance doses, were as follows:
56 Gy for the brainstem; 45 Gy for the spinal cord; 60 Gy
for the temporal lobes; 5 Gy for the lens; 50 Gy for the
optic nerves, chiasm, TMJs, and mandible; and 40 Gy for
the parotids. This plan was approved upon meeting the
following criteria: (1) the prescribed dose encompassed at
least 95% of the target volume, (2) no greater than 1% of
the GTVnx could receive ≤93% of the prescribed dose, (3)
the maximum dose point was located in the GTVnx, and
(4) the isodoses were normalised to the maximum dose,
with the chosen prescription isodose for the GTVnx equal-
ling at least 80% of the maximum dose. For the critical
organs with functional subunits organised in a series, the
dose to 5% of the volume (D5) could not exceed their toler-
ance doses, and the maximum dose delivered to 1 mL of
the cervical segment of spinal cord could not exceed 45 Gy.
For the critical organs with functional subunits organised
in parallel, the dose constraints to 33% of the volume (D33)
were less than their tolerance doses [10,13]. The actual ex-
posure doses of targets and OARs are presented in Table 2.
Chemotherapy
Of 208 patients, 127 received radiotherapy alone, 81
received chemoradiotherapy. Of 81 patients, 45 received
concurrent chemotherapy, 11 received induction and
concurrent chemotherapy, 9 received concurrent and
adjuvant chemotherapy, 5 received induction, concurrent
and adjuvant chemotherapy, and 11 received induction or
adjuvant chemotherapy. The chemotherapy regimens
were primarily based on cisplatin or on cisplatin and
5-fluorouracil (5-Fu).
Follow-up and late toxicity assessment
All patients were followed up at 3 months post-treatment.
The patients were then followed up every 3 months until
3 years post-treatment and then once a year thereafter.
Complete physical examination and indirect laryngoscopy
or fiber optic pharyngorhinoscopy were performed every
follow-up visit. Blood and biochemistry profiles, chest
radiography, abdominal ultrasonography, and magnetic
resonance imaging (MRI) or computed tomography (CT)
scan of the nasopharynx and cervical region were routine
elements of the assessment. Further investigations were
arranged as indicated. Late toxicity was evaluated accord-
ing to the LENT/SOMA (late effect of normal tissues/sub-
jective, objective, management, analytic) criteria of 1995
[14]. Radiation-induced cranial nerve injuries were defined
as symptoms or signs of cranial nerve damage without
Table 2 The actual exposure doses of targets and parts of organs at risk
Target volume Minimal dose mean Maximum dose mean Average dose mean Average fractional dose mean V95 mean Volume D33/D5 mean
(Gy) (Gy) (Gy) (Gy) (%) (Gy)
GTVnx 63.42 78.34 71.99 2.40 99.38
GTVndL 59.07 71.53 71.53 2.38 99.73
GTVndR 59.16 73.42 66.47 2.22 99.93
CTV1 54.16 77.38 67.59 2.25 99.60
CTV2 37.54 76.68 60.83 2.03 98.22
OAR
Brainstem 5.47 50.47 21.99 1.54 5% 46.13
Spinal cord 7.59 37.23 24.74 1.32 1 cc 39.45
Temporal lobes L 1.73 61.79 12.49 0.49 33% 14.76
R 2.00 61.95 12.42 0.51 15.27
Parotids L 14.68 58.30 31.62 1.18 33% 35.38
R 15.00 59.09 32.26 1.22 36.60
Temporomandibular joints L 19.34 47.54 29.22 1.15 33% 34.51
R 19.75 46.51 29.38 1.16 34.84
Optical nerves L 6.66 34.00 16.15 1.09 5% 32.58
R 6.88 33.52 16.27 1.10 32.99











Zheng et al. Radiation Oncology  (2015) 10:17 Page 4 of 11tumour recurrence. If the patient presented cranial nerve
injuries before radiotherapy and fully recovered after treat-
ments, then the recurrence of symptoms or signs of cranial
nerve damage were recorded as radiation-induced cranial
nerve injury. If the patient only partially recovered, then
exacerbations of symptoms or signs were also recorded.
Statistical methods
SPSS 13.0 (Chicago, IL) software was used for the statistical
analysis. Logistic regression was adopted for multiple-
factor analysis. P values < 0.05 were considered as statisti-
cally significant.
Results
Follow-up period and late toxic effect occurrence
The follow-up period began on the last day of radiother-
apy, and the last follow up was 31 March 2012. The
median follow-up time was 78 months (range: 60–96
months). Of 208 patients, 180 (86.5%), 13 (6.25%), 5
(2.4%), 2 (0.48%) and 4 (1.92%) patients experienced one
or more late toxic effects within 12 months, 13–24
months, 25–36 months, 37–48 months and 49–60
months after receiving treatments, respectively. The most
common late injury was cervical subcutaneous fibrosis,
with an occurrence rate of 89.9%. Hearing loss, skin dys-
trophy and xerostomia had occurrence rates of 67.8%,
47.6% and 40.9%, respectively. Trismus, temporal lobe in-
jury, cranial nerve damage, cataract and brain stem injury
had occurrence rates of 7.21%, 4.33%, 2.88%, 1.44% and
0.48%, respectively. No spinal cord injuries or mandible
injuries were found. Xerostomia decreased gradually over
time. In contrast, hearing loss, skin dystrophy, and cervical
subcutaneous fibrosis increased gradually over time
(Figure 1).
Late toxicity of the nervous system
In total, 16 patients (7.69%) had late injuries of the ner-
vous system, including 1 (0.48%) with brain stem injury, 6
(2.88%) with cranial nerve damage and 9 (4.33%) with
temporal lobe injury (Table 3). Two patients presented
grade 4 injuries of post-cranial nerves. Patients with brain
injuries exhibited varying degrees of unsteady gait, limb
weakness, memory loss and limb numbness. The patient
that developed a brain stem injury at 1 year was diagnosed
with stage T4 with the GTVnx next to the brain stem.
Cranial nerve damage was found in 1, 2, 1 and 2 patients
in years 2, 3, 4 and 5 after RT, respectively. Temporal lobe
injury was found in 4, 2, 2 and 1 patients in years 2, 3, 4
and 5 after RT, respectively. The distribution of the
T stages is shown in Table 4.
Non-nervous system toxicity
Most late injuries were assessed as grades 0–1. In rare
cases, grade 3–4 late injuries were observed as follows: 1skin injury (0.48%), 4 subcutaneous soft tissue injuries
that were severe in duration (1.92%), and 2 hearing
injuries (0.96%). No grade 3–4 injuries were observed in
the parotids, TMJs or eyes, and no late mandible injuries
were observed (Table 5).
Xerostomia was recorded in 80.8%, 66.3%, 56%, 40.9%
and 40.9% of patients within 1, 2, 3, 4 and 5 years after
RT, respectively. The incidence decreased gradually over
time and then stabilised within the 4 years after RT.
No grade 3–4 xerostomia was found (Figure 2).
The incisor distance stabilised by 1 year after RT in all
patients. Trismus was recorded in 3.37%, 3.37%, 5.29%,
5.77% and 7.21% patients within 1, 2, 3, 4 and 5 years after
RT, respectively. No grade 3–4 trismus developed. The
mean incisor distance of 208 patients was 4.54 ± 0.5 cm
before radiotherapy and decreased to 4.3 ± 0.6 cm, 4.3 ±
0.6 cm, 4.3 ± 0.7 cm, 4.2 ± 0.7 cm and 4.2 ± 0.7 cm by
years 1–5 after radiotherapy, respectively (Figure 3).
Multifactorial analysis of late injuries
Logistic multifactorial analysis was used to analyse the
independent risk factors, which included gender, age,
T stage, clinical stage and chemotherapy of late injuries
after IMRT, for NPC patients. Hearing loss was related to
chemotherapy and age (p < 0.05). Xerostomia was associ-
ated with chemotherapy (p < 0.05) (Table 6).
Discussion
For the anatomic site specificity of nasopharyngeal carcin-
oma, the irradiation field of traditional RT usually in-
volved many normal tissues, including most salivary
glands, temporomandibular joints, optical nerves, ears,
temporal lobes, and the spinal cord. However, the radical
tumour dose largely exceeded the tolerance dose of nor-
mal tissues. Cui [15] reported that the mean doses of the
optical nerves, temporal lobes, TMJs, and middle ears all
were over 63 Gy and that some were even higher than
69 Gy, with a prescription dose of 70 Gy GTVnx in
conventional RT. These high doses resulted in various late
adverse events, including hearing loss, xerostomia, and
trismus, and greatly affected the patient’s quality of life.
IMRT allows the accurate irradiation of tumours and
better protects OARs. This technique adopts an inverse
therapy planning system, optimises the prescription dose
of the set target volume and the restricted dose of
organs at risk, makes the distribution of the high dose
curve suited to the shape of the tumour target volume,
and clearly reduces the irradiation dose and volume of
nearby OARs by adjusting the radial intensity. With the
prescription doses of GTVnx, GTVnd, CTV1 and CTV2
of 68 Gy, 60 Gy to 66 Gy, 60 Gy and 54 Gy, respectively,
the mean irradiation doses reached 71.99 Gy, 66.47 Gy to
71.53 Gy, 67.59 Gy and 60.83 Gy, respectively, which
raised the irradiation dose of the target volume compared
Figure 1 The incidence of late injuries within 5 years after radiotherapy.
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radiation dose also reached 2.03 Gy to 2.4 Gy, while the
mean doses of nearby OARs, including the optic nerves,
optic chiasma, parotids, TMJs, brainstem and spinal cord,
were 16 Gy, 17 Gy, 32 Gy, 29 Gy, 12 Gy, 22 Gy and 25 Gy,
which were only one-fourth to one-half of the conven-
tional RT doses. The mean doses of D5 and D33 were also
clearly below the tolerance doses, with the mean fractions
only ranging from 0.49 Gy to 1.54 Gy (Table 2).
Studies regarding the late complications of 2-D RT and
IMRT from different radiotherapeutic centres greatly var-
ied. We selected some of the reports (Tables 7 and 8) with
many cases, a longer follow-up time (primarily >4 years)
and a consistent grading system to compare their findings.
The occurrence rate of late injuries in the nervous
system after conventional RT in NPC patients was 13.5%-
42.8% [2,3,16], the rate of late injuries in the nervous sys-
tem over grade 3 was 1%-4.5% [3-5]. The stage T3 or T4
NPC patients always required the additional administra-
tion of 6–8 Gy to the skull base or to the intracranium.
After an irradiation dose of 70 Gy to the nasopharynx, the
irradiation dose of the temporal lobes and cranial nerves
on both sides of the cavernous sinus reached over 70 Gy,Table 3 Grades of late injuries of nervous system
Total number 208
Late injury Total Total % Distribution of patients
1 2 3 4
n Grade Grade Grade Grade
Brain stem 1 0.48 0 1 0 0
Temporal lobe 9 4.33 0 8 1 0
Cranial nerve 6 2.88 0 4 0 2
Spinal cord 0 0 0 0 0 0which lead to a greatly increased risk of injury. Of 200
NPC patients with more than 5 years survival after con-
ventional RT, Sumitsawan [3] reported that 7% had brain
injuries and 1.5% had severe injuries. Kong’s [2] study
showed that late injuries of the spinal cord and of the
cranial nerve affected up to 9.8% and 31.8% of patients,
respectively, within 5 years after 2-D RT. In our research,
83 patients (40%) were classified as stage T3 or T4. Al-
though the mean irradiation dose of nasopharynx reached
72 Gy, no late spinal injuries occurred, 1 (0.48%) brain-
stem injury occurred, 6 (2.88%) cranial nerve injuries
occurred and 9 (4.33%) temporal lobe injuries occurred.
Most patients with temporal lobe injuries were stage T3
or T4 of disease, which might have resulted from the high
dose of RT to the temporal lobes because of large tumour
invasion to the skull base or to the intracranium. Zhou
[17] and Su [18] conducted long-term follow-up studies
regarding radiation-induced temporal lobe injury in
patients with NPC after IMRT. Both studies showed that
the temporal lobe injuries were related to the T stage,
which was similar to our results. However, the reported
incidence of temporal lobe injury was 16% in Zhou’s studyTable 4 The distribution of T stage of patients who had
late nervous system injuries








T2 1 1 2
T3 4 3 7
T4 1 4 1 6
Total 1 9 4 2 16
Table 5 Distribution of late injuries occurrence in non-
nervous system
Total number 208
Late injury Total Total % Distribution of patients
1 2 3 4
n Grade Grade Grade Grade
Parotid 85 40.9 75 10 0 0
Ear 141 67.8 98 41 2 0
Subcutaneous
soft tissue
187 89.9 139 44 4 0
Skin 99 47.6 81 17 1 0
Temporomandibular
joints
15 7.21 10 5 0 0
Eye 3 1.44 2 1 0 0
Mandible 0 0 0 0 0 0
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259 NPC patients, respectively, and 5 years of follow-up.
These reported incidence rates were higher than the inci-
dence rates reported in our present study. These results
may differ because our study excluded some patients who
had recurrence or metastasis; thus, the T3-4 cases were
less than 40%. In addition, Zhou’s [17] study showed that
the median latency of temporal lobe injury detection in
NPC patients after IMRT was 36.85 months with 5 years
of follow-up. Moreover, Su’s [18] study showed that the
median latency of temporal lobe injury detection in NPC
patients after IMRT was 30 months and that the longest
latency of temporal lobe necrosis was 56 months. Both
studies suggested that the incidence of temporal lobe
injury increased gradually over time after IMRT, which
was similar to the findings of our study. Although the inci-
dence rates of temporal lobe and cranial nerve damage
were relatively low in the present study, the incidence
rates increasing year by year in the 5 years of follow-up.
One patient with a grade 2 brainstem injury and stage
T4 (cavernous sinus) was included in our study. For this
patient, the highest irradiation dose of the brainstem wasFigure 2 The incidence and grade of xerostomia.54.54 Gy, with a mean dose of 28.79 Gy, which suggested
that the injury might have resulted from incidentally high
sensitivity of the brainstem to irradiation.
The highest occurrence rate (57% to 99.7%) of late com-
plications after NPC conventional therapy was xerostomia
[2,3,16]. Kong [2] reported that 99.7% of NPC patients
had varying degrees of xerostomia and that 23.5% had
grade 3–4 xerostomia after conventional RT. To achieve a
nasopharynx tumour dose of 70 Gy in conventional ther-
apy, the dose of most parotids was greater than 60 Gy.
Cooper [19] reported that more than a 50 Gy dose to the
parotids would result in irreversible injuries and lead to
long-term xerostomia. Hsiung [11] compared the extent
of injuries to the parotids after IMRT and conventional
RT by measuring the maximum excretion rate (MER) of
saliva after stimulating the parotids in treated NPC
patients. The results showed that the MER of parotids in
patients with IMRT recovered by more than 25% after
6 months in 64.5% of patients who received a mean dose
of 43.9 Gy (33.2–58.8 Gy). Kwong [7] evaluated parotid
function in early phase NPC patients after IMRT and
found that the basic flow of parotids recovered by more
than 25% in 60% of patients who received a mean dose of
38.8 Gy (32–46.1 Gy). The above two studies regarding
parotid function after IMRT confirmed that parotid func-
tion could recover gradually when the irradiation dose
was below 50 Gy. In our study, the mean irradiation dose
of one-third of the bilateral parotid volume (D33) was
approximately 36 Gy, and the mean dose was below
33 Gy. During the 5 years of follow-up, no grade 3 or
grade 4 xerostomia was presented. Although the incidence
of xerostomia in the first year after IMRT was 80.8%, the
symptoms gradually alleviated decreased to 40.9% during
the 4th year and then tended to be stable. Figure 2 shows
that grade 1–2 xerostomia decreased gradually, whereas
grade 0 xerostomia increased during the first 4 years of
the follow-up period after IMRT and then showed only
slight changes after the 4th year. Moreover, primarily
grade 1 reduced to grade 0 xerostomia occurred 2 to
Figure 3 The change of incisor distance of 208 patients 1-5 year after radiotherapy.
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clearly facilitate salivary gland protection over time. Some
long-term follow-up (more than 4 years) studies examined
late toxicity effects in patients with NPC after IMRT
[13,20,21]. Xiao [13] reported xerostomia incidence and
development trends that were similar to our xerostomia
incidence and development trends. These authors showed
that the extent of xerostomia was clearly alleviated by 3 to
12 months after IMRT and that grade 1 back to 0 xerosto-
mia cases were primarily observed at 1 year after treat-
ment. Because their observations ceased during the 4th
year after RT, the period at which the variation stabilised
was not displayed. Wu [20] also reported that the severity
of xerostomia decreased over time; however, no grade 3–4
xerostomia could be found at 2 years after treatment.
Wang’s [21] study showed that xerostomia could beTable 6 Multiple-factor analysis of late injuries
Salivary glands Ears
Gender 0.911 (0.439-1.890) 1.015 (0.983-1.049
P > 0.05 P > 0.05
Age 0.987 (0.959-1.017) 3.311 (1.322-8.288
P > 0.05 P = 0.011
Stage (I-II vs III-IV) 1.455 (0.673-3.143) 1.919 (0.833-4.42)
P > 0.05 P > 0.05
T Stage (T1-2vs T3-4) 0.977 (0.454-2.101) 0.926 (0.400-2.144
P > 0.05 P > 0.05
Radiotherapy vs Chemoradiotherapy 2.249 (1.186-4.265) 4.012 (1.839-8.749
P = 0.013 P = 0.000relieved to the lowest degree within 3–6 months after
IMRT and that the condition showed only slight changes
after 1 year. This result differed somewhat from the above
two studies and from our present study. This difference
might be attributable to the presence of grade 3 xerosto-
mia (2.5%-2.7%) 1–5 years after RT in Wang’s [21]
research.
Trismus, which is induced by the high irradiation dose
of bilateral TMJs in conventional RT, was also a common
complication in NPC patients with long-term survival
after conventional RT, with occurrence rates of 12%-41.5%
overall and 2.9%-3.3% for grade 3 or 4 trismus [2,3,5,16].
Chen M [22] analysed the incisor distance of 352 NPC
patients before conventional RT and at 6 months after RT.
The occurrence rate of trismus was 58.5% and the rate of
grade 3 or grade 4 trismus was 7.1%, which was muchHR (95% CI; P)
TMJS Skin Subcutaneous soft tissue
) 1.766 (0.508-6.141) 0.759 (0.376-1. 53) 6.046 (0.775-47.153)
P > 0.05 P > 0.05 P > 0.05
) 1.035 (0.983-1.089) 0.994 (0.967-1.022) 1.005 (0.957-1.054)
P > 0.05 P > 0.05 P > 0.05
2.511 (0.462-13.656) 0.720 (0.336-1.54) 2.081 (0.596-7.267)
P > 0.05 P > 0.05 P > 0.05
) 2.496 (0.469-13.280) 1.759 (0.831-3.727) 0.776 (0.230-2.618)
P > 0.05 P > 0.05 P > 0.05
) 0.681 (0.211-2.203) 1.282 (0.682-2.409) 3.823 (0.998-14.649)
P > 0.05 P > 0.05 P = 0.050
Table 7 The study reports of late complications occurrence after conventional RT
Xerostomia Ears Subcutaneous
soft tissue
Skin reaction Trismus Mandible Eyes Brain Spinal cord Cranial nerve
Sanguineti [5] 1954-92 ≥G3 2.6% ≥G3 4.2% ≥G3 1.1% ≥G3 2.9% ≥G3 2.6% ≥G3 1.1% ≥G3 2.4% ≥G3 4.5%
N = 378
Perez [4] 1956-86 ≥G3 10% ≥G3 2% ≥G3 1%
N = 143
Yeh [16] 1983-98 90.3% 54% 25% 12% 6% 21%
N = 849 ≥G3 12.4%
Lee [24] 1994-97 ≥G3 8.0% ≥G3 6.5% ≥G3 0.3% ≥G3 0.9% ≥G3 0.6% ≥G3 0.3%
N = 325
Sumitsawan [3] 2003-05 97.5% 82.5% 62.5% 56% 41.5% 5.5% 7.0% 6.5%
N = 200 ≥G3 2.5% ≥G3 36% ≥G3 4% ≥G3 1.5% ≥G3 3% ≥G3 0.5% ≥G3 1.5%
Kong [2] 99.7% 67.0% 89.0% 81.2% 28.3% 0.6% 12.0% 1.2% 9.8% 31.8%
N = 336 ≥G3 23.5% ≥G3 22.0% ≥G3 23.6% ≥G3 16.4% ≥G3 3.3%
This study N = 208 40.9% 67.8% 89.9% 47.6% 7.21% 0% 1.44% 4.80% 0% 2.88%











Table 8 The study reports of late complications occurrence after IMRT
Xerostomia Ears Subcutaneous Soft tissue Skin reaction Trismus Mandible Eyes Brain Spinal cord Cranial nerve
Xiao [13] 2001-05 61.8% 91.2% 94.1% 35.3% 7.4% 0% 1.5% 17.6% 4.4%
N = 68 MFU* = 54 m ≥G3 0% ≥G3 0% ≥G3 1.5% ≥G3 0% ≥G3 0% ≥G3 0% ≥G3 0% ≥G3 0% ≥G3 0%
Chen YY [23] 2001-04 5.7%
N = 211 MFU* = 48 m ≥G3 0%
Su [18] 2001-08 15.4%
N = 259 MFU* = 40 m
Zhou [17] 2003-06 16%
N = 305 MFU* = 48.9 m
Wang [21] 2003-06 ≥G3 2.7% ≥G3 0% ≥G3 0.14% ≥G3 0.3% ≥G3 0.7% ≥G3 0% ≥G3 0.14%
N = 695 MFU* = 66.4 m
Wu [20] 2006-09 ≥G3 0% ≥G3 10% ≥G3 2% ≥G3 1%
N = 249 MFU* = 54.1 m
This study 2003–07 N = 208 MFU* = 78 m 40.9% 67.8% 89.9% 47.6% 7.21% 0% 1.44% 4.80% 0% 2.88%
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D33 of TMJs was below 35 Gy, and the mean dose was
below 30 Gy, which highly protected TMJ function. Tris-
mus was identified in 7.21% of patients with 5 years of
follow-up, and no grade 3 or grade 4 trismus was observed.
This result was similar to Chen YY’s [23] and Xiao’s [13]
reports using IMRT, in which 5.7% and 7.4% of NPC pa-
tients had grade 1–2 trismus after IMRT with more than
4 years of follow-up, respectively, and no severe trismus
was presented. Our analysis also demonstrated that the
change in the incisor distance of patients stabilised by
1 year after RT. This variation trend was also similar to
that described by Chen YY [23] and by Xiao [13].
Hearing loss was also a common complication in NPC
patients after conventional RT. The occurrence rate for
hearing loss ranged from 54% to 82.5% in all types of clin-
ical reports [2,3,5,16,24]. Although the occurrence rates of
hearing loss in studies by Yeh [16] and by Kong [2] were
similar to this study, the occurrence rates of over grade 3
hearing loss were 12.4% and 22%, respectively. Sumitsa-
wan’s [3] study reported that the occurrence rate of over
grade 3 hearing loss was as high as 36%, while only a
0.96% occurrence rate of over grade 3 hearing loss was
found in this study, which indicated that the occurrence
rate of hearing loss was significantly improved by IMRT.
This result was similar to that reported by Xiao [13]; al-
though the incidence rate of grade 1–2 hearing loss was
91.2%, no grade 3–4 hearing loss was observed. Our study
also showed that the incidence of hearing loss increased
gradually during the 5 years of follow-up after IMRT,
which suggested that hearing loss presented gradually over
time after RT and that once hearing loss occurred, it could
not be recovered.
In addition, this study showed that the late toxicities of
skin and subcutaneous tissues all gradually increased over
time after RT. Grade 3–4 skin dystrophy and subcutane-
ous fibrosis were less frequent compared with those
reported by conventional RT studies [2-5,16,24]. However,
in the present study, lower neck and supraclavicular fossae
were irradiated using the half-beam technique with con-
ventional RT. The data regarding the late toxicities of skin
and subcutaneous induced by IMRT could not be pre-
sented objectively.
The risk factors of late injuries after RT in NPC patients
include age, clinical stage and chemotherapy [3,16,25],
suggesting that patients with locoregionally advanced
disease would tend to develop late injuries after RT. In
Zhou’s [17] study using IMRT, the categorisation of T
stages was also an independent predictor of temporal lobe
injury by multivariate analysis. However, in our study,
multifactorial analysis showed that most late non-nervous
system injuries of NPC patients receiving IMRT had no
significant correlation with age, gender, clinical staging,
T stage or chemotherapy; however, xerostomia andhearing loss were related to chemotherapy and age. This
result may be associated with the low incidence of late in-
jury, particularly for conditions over grade 3. We did not
perform multifactorial analysis for the late toxicity of the
nervous system because the incidence rates of brain stem
injury (0.48%), cranial nerve damage (2.88%) and temporal
lobe injury (4.33%) in this study were too low.Conclusion
In summary, IMRT exhibited advantages for reducing most
late toxicities of NPC patients with long-term survival.
Through the 5 years follow-up after IMRT, we found
xerostomia could be eased or gradually returned to normal
over time and that trend showed only slight changes after
the 4 years. The change in the incisor distance of patients
stabilised by 1 year after RT, while hearing loss, skin dys-
trophy, subcutaneous fibrosis and nervous system injuries
increased gradually over time. However, our study selected
the patients who survive more than five years, and patients
with recurrence or metastasis were excluded; thus, these
results may be biased to some degree, particularly for late
toxicities of the nervous system.
In addition, this study did not perform dosimetric analysis,
and we will further study the relationship between sensitive
organs and the dosimetry of NPC patients with IMRT.
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